Brand name: Auvi-Q
FDA approves Teva's Cinqair (reslizumab) Injection
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
Reslizumab
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
Reslizumab | Teva UK
Teva files MAA for asthma treatment reslizumab
TA479 Review decision paper
Older Patients with Asthma Do Well with Reslizumab | RT
How patients use CINQAIR® (reslizumab) Injection Cost Support Program Card
Cinqair Reslizumab Injection
A program supporting CINQAIR® (reslizumab) Injection patients
Reslizumab (Cinqair) Approved to Treat Severe Asthma | RT
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Dosing and Administration
Reslizumab Reslizumab | Teva | Bioz
CINQAIR® (reslizumab) Injection – About Asthma Control
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Reslizumab Overview - Creative Biolabs
Cinqair (Reslizumab) 100mg/10mL Injection – Apothera
Discount helps NICE flip-flop on Teva's severe asthma contender, Cinqair | Fierce Pharma
NICE changes mind and backs new drug for severe asthma | Nursing Times
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
761033Orig1s000
